VALN - Valneva SE Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

VALN

VALNEVA SE

NASDAQ

$6.43

▼ DOWN 1.91% (-0.13)

KEY STATISTICS

Market Cap$609.71 M

52w High$12.23

52w Low$4.75

Dividend Yield—

Frequency—

P/E-3.05

Volume22.29K

Shares Out.94.82M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Thomas Lingelbach

ABOUT

SECTOR

Healthcare

WENT PUBLIC

May 5, 2021

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

674

PRICE TARGET

Target High$11.00

Target Low$11.00

Target Median$11.00

Target Consensus$11.00

UPCOMING EARNINGS

DateNov 19, 2026

DayThursday

Rev. Est.$43.79M

NOV

THU

PRICE

$6.43 ▼ DOWN 1.91% (−$0.13)

About Valneva SE

https://valneva.com ↗

Valneva SE develops and commercializes specialty prophylactic vaccines for infectious diseases, including Japanese encephalitis, cholera, COVID-19, Lyme disease, and chikungunya, with global partnerships and a pipeline of clinical-stage candidates.

INDUSTRY

Biotechnology

A PRODUCT VALNEVA SE IS KNOWN FOR

IXCHIQ

IXCHIQ is the world's first licensed single-shot vaccine against chikungunya, approved in Europe, Canada, and Brazil, and remains a key product in Valneva's portfolio despite US license withdrawal in early 2026.

COMPETITORS

COMPETITOR

Revenue by Products

PRODUCT	FY2022	FY2023	FY2024	FY2025
IXIARO	$41.37M	$73.48M ▲	$94.07M ▲	$98.42M ▲
DUKORAL	$17.34M	$29.77M ▲	$32.3M ▲	$31.91M ▼
Third Party Products	$26.55M	$35.67M ▲	$33.19M ▼	$19.16M ▼
Others Products	—	$3.09M	—	—
Other Services	—	—	$1.13M	$87K ▼

Revenue by Geography

REGION	FY2022	FY2023	FY2024	FY2025
UNITED STATES	$21.99M	$32.96M ▲	$48.59M ▲	$53.61M ▲
CANADA	$18.9M	$28.19M ▲	$32.32M ▲	$30.13M ▼
GERMANY	$20.34M	$13.5M ▼	$18.37M ▲	$17.47M ▼
FRANCE	$2.63M	$5.87M ▲	$7.22M ▲	$14.67M ▲
Nordics	—	$12.7M	$13.94M ▲	$13.9M ▼
Other Europe	—	$9.34M	$9.06M ▼	$13.88M ▲
AUSTRIA	$13.75M	$14.58M ▲	$15.9M ▲	$9.47M ▼
Rest Of World	—	$16.31M	$4.69M ▼	$8.9M ▲